Clinical trial
A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
NCT03030612 is registered in ClinicalTrials.gov with OncoVerity, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
- Lead sponsor
- OncoVerity, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- December 31, 2016
- Completion date
- August 31, 2022
- Enrollment
- 38 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.